CDKN2A and pancreatic neoplasm: Corresponding to the higher un-responsiveness of pancreatic cancer patients with KRAS mutation or CDKN2A deletion, we found that MMP14 and PKM2 were highly expressed in drug un-responsive patients (Figure 7D).